Dornase alfa. A practical guide to patient selection and drug use in cystic fibrosis

BioDrugs

Volumn 8, Issue 6, 1997, Pages 439-445

  Shah, Pallav L ^a   Hodson, Margaret E ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

AEROSOL; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG INFECTION; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; SPUTUM; VISCOELASTICITY;

EID: 0030699170     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708060-00004     Document Type: Short Survey

References (32)

1. Amstrong JB, White JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950; 11: 739-42
2. Elmes PC, White JC. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax 1953; 8: 295-300
3. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959; 24: 739-45
4. Potter J, Matthews LW, Lemm J, et al. Composition of pulmonary secretions from patients with and without cystic fibrosis. Am J Dis Child 1960; 100: 493-5
5. Matthews LW, Spector S, Lemm J, et al. Studies on pulmonary secretions. I. The overall composition of secretions from patients with cystic fibrosis. bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963; 88: 199-204
6. Picot R, Das I, Reid L. Pus deoxyribonucleic acid and sputum viscosity. Thorax 1978; 33: 235-42
7. Lethem MI, James SL, Marriott C, et al. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 1990; 3: 19-23
8. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. J Am Med Assoc 1968; 205: 312-13
9. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968; 98: 697-8
10. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-92
11. Zahm JM, Girod de Bentzmann S, Deneuville E, et al. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J 1995; 8: 381-6
12. Shah PL, Scott SF, Knight RA, et al. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996; 51: 119-25
13. Dulfano MJ, Adler KB. Physical properties of sputum. VII. Rheologic properties and mucociliary transport. Am Rev Respir Dis 1975; 112: 341-7
14. Puchelle E, Zahm JM, Polu JM, et al. Drug effects on visco-elasticity of mucus. Eur J Respir Dis 1980; 61 Suppl. 110: 195-208
15. Shih CK, Litt M, Khan MA, et al. Effect of nondialyzable solids concentration and viscoelasticity on ciliary transport of tracheal mucus. Am Rev Respir Dis 1977; 115: 989-95
16. King M, Gilboa A, Meyer FA, et al. On the transport of mucus and its rheologic stimulants in ciliated systems. Am Rev Respir Dis 1974; 110: 740-5
17. Laube BL, Auci RA, Shields DE, et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 752-60
18. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42
19. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase 1 in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199-202
20. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolised recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-51
21. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1991; 122: 1-9
22. Shah PL, Bush A, Canny GJ, et al. Recombinant human DNase 1 (rhDNase) in cystic fibrosis patients with severe pulmonary disease: a short-term double-blind study followed by six months open-label treatment. Eur Respir J 1995; 8: 954-8
23. Johnson C, Pulmozyme Severe Lung Disease Study Group. A multicentre, double-blind, placebo controlled study to evaluate the safety and efficacy of aerosolized rhDNase therapy in patients with cystic fibrosis who have advanced lung disease [abstract]. Pediatr Pulmonol 1994; Suppl. 10: 115
24. Schidlow DV. Use of aerosolised dornase alfa in cystic fibrosis: safety, patient selection and dosing. Dornase alfa Clin Ser 1994; 1 (3): 1-6
25. Accurso FJ. Aerosolised dornase alfa in cystic fibrosis patients with clinically mild lung disease. Dornase alfa Clin Ser 1995; 2 (1): 1-6
26. Hubbard RC, McElvaney NG, Birrer P, et al. A preliminary study of aerosolised recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326: 812-5
27. Cipolla D, Gonda I, Shire SJ. Characterisation of aerosol of recombinant deoxyribonuclease I (rhDNase) generated by jet nebulisers. Pharm Res 1994; 11: 491-8
28. Fiel SB, Fuchs HJ, Johnson C, et al. Comparison of three jet nebuliser aerosol delivery systems used to administer recombinant human DNase 1 to patients with cystic fibrosis. Chest 1995; 108: 153-6
29. Shah PL, Scott SF, Geddes DM, et al. An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J 1997; 10: 1261-6
30. Green JD. Pharmaco-toxicological expert report: Pulmozyme (rhDNase), Genentech Inc. Hum Exp Toxicol 1994; 13 Suppl 1: S1-S42
31. Wilmott RW, Amin RS, Colin AA, et al. Aerosolised recombinant human DNase in hospitalised cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914-7
32. Shah PL, Scott SF, Hodson ME. Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNase I. Respir Med 1994; 88: 313-5